Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid CAS 486460-00-8 Purity ≥99.5% (HPLC) Sitagliptin Phosphate Monohydrate Intermediate

Short Description:

Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid

CAS: 486460-00-8

Purity: ≥99.5% (HPLC)

Appearance: White to Off-White Powder

Intermediate of Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9) for the treatment of type II diabetes mellitus

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Supply Sitagliptin Phosphate Monohydrate Related Intermediates:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydrate API CAS 654671-77-9
2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydrate Intermediate CAS 486460-21-3

Chemical Properties:

Chemical Name	Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid
Synonyms	(R)-Sitagliptin N-Boc-Acid Impurity
CAS Number	486460-00-8
CAT Number	RF-PI1192
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C15H18F3NO4
Molecular Weight	333.31
Melting Point	136.0~138.0℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Powder
Identification by HPLC	The Retention Time of Sample is Concordant With Reference Standard
Loss on Drying	≤0.50%
Sulphated Ash	≤0.50%
Heavy Metals	<20ppm
Isomer	≤0.50%
Related Substances
Impurity A	≤0.50%
Any Other Single Impurity	≤0.50%
Total Impurities	≤0.50%
Purity	≥99.5% (HPLC)
Test Standard	Enterprise Standard
Usage	Intermediate of Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid (CAS: 486460-00-8) is an important intermediate for the preparation of sitagliptin. Sitagliptinphosphate is the first dipeptidase -IV(DPP-4) inhibitor approved by FDA in 2006. It is used for the treatment of type II diabetes mellitus. It has obvious hypoglycemic effect when used alone or in combination with metformin and pioglitazone, and it is safe to take, well tolerated, with few adverse reactions. In August 2009, the drug was approved by the European Union as a first-line drug for the treatment of type 2 diabetes. After 2011, one after another countries have approved the combination of sitagliptin phosphate and alpha glycosidase inhibitors or insulin. Sitagliptin phosphate is the first FDA-approved dipeptidyl peptidase-IV inhibitor to be used in the treatment of type 2 diabetes by far, under the trade name Januvia.